About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Clinical Trials in Illinois | 19,692 Studies Near You | Clareo Health

Clinical Trials LocationsIllinois

Clinical Trials in Illinois

Discover 19,692 clinical trials near Illinois. Find research studies in your area.

Browse by condition:

Breast Cancer Lung Cancer Prostate Cancer Colorectal Cancer Melanoma Leukemia Lymphoma Pancreatic Cancer

Filters

Sort by

Status

Recruiting(Enrolling)

Not yet recruiting

Active, not recruiting

Enrolling by invitation(Enrolling)

Completed

Terminated

Phase

Early Phase 1

Phase 1

Phase 1/Phase 2

Phase 2

Phase 2/Phase 3

Phase 3

Phase 4

Not Applicable

Eligibility

Accepts healthy volunteers

Showing 18841-18860 of 19,692 trials

COMPLETEDPhase 3103 miles

Effects of Antidepressants on Sexual Functioning

NCT00051259

The purpose of this trial is to study the effects of two depression medications on sexual functioning.

Major Depressive Disorder (MDD)

GlaxoSmithKline420 participantsStarted Jan 2003

Berkeley, California, United States • Beverly Hills, California, United States • La Mesa, California, United States +20 more locations

COMPLETEDPhase 4122 miles

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

NCT00573508

Evaluate the effect of VESIcare® on symptom bother for subjects with OAB

Urinary Bladder, Overactive

Astellas Pharma Inc768 participantsStarted Aug 2007

Montgomery, Alabama, United States • Phoenix, Arizona, United States • Tucson, Arizona, United States +56 more locations

Find Trials by Condition in Illinois

Breast Cancerin Illinois Lung Cancerin Illinois Prostate Cancerin Illinois Colorectal Cancerin Illinois Melanomain Illinois Leukemiain Illinois Lymphomain Illinois Pancreatic Cancerin Illinois Ovarian Cancerin Illinois Brain Cancerin Illinois Diabetes

Data from ClinicalTrials.govTerms

COMPLETEDPhase 3125 miles

A New Tablet Containing Two FDA-Approved Drugs In HIV-Infected Patients Who Have Not Received Prior Therapy

NCT00053638

This is a 48-week study to evaluate the safety and efficacy of a new tablet formulation containing two FDA-approved drugs in HIV-infected patients who have not received prior therapy. This tablet will be taken with one of two FDA-approved drugs as a once-daily regimen. Study physicians will evaluate subjects to determine if they have certain medical conditions, laboratory test values, medication use, or drug allergies that would exclude them from the study.

GlaxoSmithKline345 participantsStarted Feb 2003

Phoenix, Arizona, United States • Fountain Valley, California, United States • Los Angeles, California, United States +55 more locations

COMPLETEDPhase 2125 miles

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

NCT00096720

Study participants who have been clinically diagnosed with Parkinson disease will receive no treatment, treatment with either levodopa, or treatment with Mirapex for a period of 12 weeks. Over the course of the study subjects will travel to the Institute for Neurodegenerative Disorders (IND) in New Haven, Connecticut for brain imaging.

Parkinson DiseaseParkinsonian Syndrome

Institute for Neurodegenerative Disorders112 participantsStarted Feb 2004

Oxnard, California, United States • Englewood, Colorado, United States • New Haven, Connecticut, United States +10 more locations

COMPLETEDPhase 4125 miles

The Effect of Nebivolol in Hypertensive Patients With Coronary Artery Disease

NCT00673075

This study is being done to see if the blood pressure lowering effect of an approved drug nebivolol is comparable to that of another approved drug carvedilol for the treatment of hypertension in patients who have coronary artery disease.

HypertensionCoronary Artery Disease

Forest Laboratories39 participantsStarted May 2008

Birmingham, Alabama, United States • Peoria, Arizona, United States • Buena Park, California, United States +31 more locations

COMPLETEDPhase 2125 miles

Study to Assess the Safety and Efficacy of CD-NP in the Treatment of Patients With Acute Decompensated Heart Failure

NCT00839007

The primary objective of the study is to assess the safety and tolerability of IV administration of CD-NP and the dose relationship of CD-NP on improvement of clinical symptoms and renal function in ADHF patients.

Acute Decompensated Heart Failure

Nile Therapeutics77 participantsStarted Jun 2009

Los Angeles, California, United States • Torrance, California, United States • Jacksonville, Florida, United States +18 more locations

COMPLETEDPhase 3125 miles

A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD

NCT00419744

The purpose of this study is to determine if SYMBICORT® delivered via a pressurized metered-dose inhaler, referred to as a pMDI, is effective in preventing COPD exacerbations.

Chronic Obstructive Pulmonary Disease

AstraZeneca1,200 participantsStarted Jan 2007

Jasper, Alabama, United States • Mobile, Alabama, United States • Tucson, Arizona, United States +137 more locations

COMPLETEDPhase 2/3125 miles

Dose Ranging Study With LT, Monotherapy, PPAR

NCT00240383

A Randomized, Double-Blind, Dose-Ranging, Dose Comparison-Controlled Trial to Determine the Safety and Efficacy of BMS-298585 in Subjects with Type 2 Diabetes

Diabetes Mellitus II

Bristol-Myers Squibb1,260 participantsStarted May 2002

Anniston, Alabama, United States • Birmingham, Alabama, United States • Huntsville, Alabama, United States +269 more locations

TERMINATEDPhase 3125 miles

A Study of Abatacept in Patients With Active Crohn's Disease

NCT00406653

The purpose of this clinical research study is to learn if abatacept can improve signs and symptoms of active Crohn's Disease in patients who have not had an adequate response to other therapies. The safety of this treatment will also be studied.

Crohn's Disease

Bristol-Myers Squibb451 participantsStarted Dec 2006

Birmingham, Alabama, United States • Los Angeles, California, United States • Sacramento, California, United States +98 more locations

COMPLETEDPhase 1155 miles

Safety Study of Imexon Plus Gemcitabine in Untreated Pancreatic Adenocarcinoma

NCT00327327

AMP-004 is a Phase 1b dose escalation trial designed to evaluate the safety of the new drug imexon in combination with an approved drug, gemcitabine, for the treatment of patients with previously untreated pancreatic cancer. The treatment consists of dosing with both imexon and gemcitabine on days 1, 8, and 15 of each 28 day cycle. The study is designed to determine the highest doses of the two drugs that can be safely combined together.

Pancreatic Adenocarcinoma

AmpliMed Corporation105 participantsStarted Feb 2004

Tucson, Arizona, United States • Ocoee, Florida, United States • Indianapolis, Indiana, United States +6 more locations

COMPLETEDPhase 3252 miles

A Randomized Clinical Trial of Cognitive-Behavioral Treatment for Post-Traumatic Stress Disorders in Women

NCT00032617

The purpose of the proposed DVA cooperative study is to evaluate the efficacy of exposure therapy for treating PTSD and associated problems in female veterans and active duty military personnel. We propose to compare exposure therapy, Prolonged Exposure, with a comparison therapy that focuses on current problems, Present Centered Therapy. The study is a randomized clinical trial involving 384 female veterans and active duty personnel in 11 VA medical centers and 1 DoD medical center. All subjects, even self-referrals, will enter the study through referrals by mental health clinicians at the participating sites. Following informed consent, subjects will be screened for inclusion and exclusion diagnoses. If they meet these criteria and agree to participate, they will be randomly assigned to one of the two treatments, which will occur weekly for 10 weeks. Subjects will be assessed before treatment, immediately following treatment, and 3 and 6 months after the end of treatment. The primary outcome is PTSD severity. Secondary outcomes are anxiety and depression. Exploratory outcomes include associated features of PTSD, such as dissociation and substance abuse; psychosocial functioning, quality of life, physical health, satisfaction with treatment, and service utilization. Both treatments will be described in detail in a treatment manual and monitored intensively to ensure that they are administered correctly.

Stress Disorders, Post-Traumatic

US Department of Veterans Affairs284 participantsStarted Aug 2002

Denver, Colorado, United States • Bay Pines, Florida, United States • Decatur, Georgia, United States +10 more locations

COMPLETEDPhase 2252 miles

Study of CTS-1027 in Hepatitis C Patients

NCT00570336

The purpose of this study is to determine if CTS-1027 can lower elevated liver enzymes in patients with chronic HCV infection.

Chronic Hepatitis C Virus Infection

Conatus Pharmaceuticals Inc.87 participantsStarted Dec 2007

Birmingham, Alabama, United States • La Jolla, California, United States • San Diego, California, United States +16 more locations

COMPLETEDNA303 miles

Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer

NCT00049465

RATIONALE: Telephone counseling by trained counselors may enhance the well-being and quality of life of patients who have undergone stem cell transplantation for cancer. PURPOSE: Randomized clinical trial to compare the effectiveness of standard follow-up care with extended follow-up care in treating patients who have undergone stem cell transplantation for cancer.

Fred Hutchinson Cancer CenterStarted Aug 1998

Stanford, California, United States • Denver, Colorado, United States • Denver, Colorado, United States +6 more locations

COMPLETEDPhase 2310 miles

Ispinesib In Patients With Advanced Or Metastatic Non-Small Cell Lung Cancer

NCT00085813

This study was designed to determine how effective and safe Ispinesib is in treating locally advanced or metastatic Non-small Cell Lung cancer in patients who have received a platinum-based chemotherapy and whose disease continues to progress. Treatment involves a 1-hr treatment given intravenously (IV), repeated once every 21 days. A patient may continue treatment as long as they are benefiting from the treatment. Blood samples will be taken at specific times over 24 hr period to measure the amount of drug in your body at specific times after the drug is given. Blood samples will also be taken for routine lab tests such as complete blood counts and clinical chemistries. Physical exams will be performed before each treatment.

Non-Small-Cell Lung Cancer

GlaxoSmithKline70 participantsStarted Dec 2003

Scottsdale, Arizona, United States • Jacksonville, Florida, United States • Rochester, Minnesota, United States +8 more locations

COMPLETEDPhase 1337 miles

A Phase 1 Safety Study of Single and Repeated Doses of JSM6427 (Intravitreal Injection) to Treat AMD

NCT00536016

The purpose of this study is to determine the way and rate that the study medication, JSM6427 a potent, highly specific integrin α5β1-antagonist is absorbed, broken-down and eliminated from the body when it is given as a single dosage strength by injection into the eye. Repeated dosages will also be given to determine the highest safe dose.

Macular Degeneration

Jerini Ophthalmic36 participantsStarted Sep 2007

Beverly Hills, California, United States • Boston, Massachusetts, United States • Royal Oak, Michigan, United States +6 more locations

COMPLETEDPhase 4528 miles

A Study for Type 2 Diabetic Patients

NCT00548808

The purpose of the study is to compare the insulin lispro low mixture (1, 2 or 3 daily injections) with insulin glargine (alone or with 1, 2 or 3 insulin lispro daily injections) on lowering the blood sugar level

Type 2 Diabetes Mellitus

Eli Lilly and Company426 participantsStarted Nov 2007

Daw Park, South Australia, Australia • East Ringwood, Victoria, Australia • Nedlands, Western Australia, Australia +22 more locations

COMPLETEDPhase 1648 miles

Pharmacokinetics of Efavirenz in HIV-1 Infected Subjects With Hepatic Impairment

NCT00162097

The purpose of the study was to assess the steady-state pharmacokinetics (PK) of efavirenz (EFV) in human immunodeficiency virus type 1 (HIV-1) infected subjects on stable antiretroviral regimens containing EFV, and having selected degrees of hepatic impairment or normal hepatic function.

HIV InfectionsHepatic Impairment

Bristol-Myers Squibb21 participantsStarted Nov 2004

Baltimore, Maryland, United States • San Antonio, Texas, United States • Richmond, Virginia, United States +1 more locations

UNKNOWN730 miles

Study of Genetic Risk Factors for Spina Bifida and Anencephaly

NCT00031122

The purpose of this study is to describe the genetic contribution to the neural tube defects spina bifida (SB) and anencephaly (A), which includes identifying patients, defining the roles of certain genes, and studying gene-environment interactions.

Spina BifidaAnencephaly

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)1,100 participantsStarted Sep 2000

Philadelphia, Pennsylvania, United States • Houston, Texas, United States

COMPLETEDPhase 1/2786 miles

Rituximab Treatment of Graves' Dysthyroid Ophthalmopathy

NCT00424151

This study is designed to treat patients with Graves' disease with Rituximab in an attempt to prevent or reverse the physically deforming and debilitating consequences of this disease.

Graves' Dysthyroid OphthalmopathyThyroid Related Orbitopathy

Silkiss, Rona Z., M.D., FACS12 participantsStarted Dec 2006

Oakland, California, United States • New York, New York, United States

COMPLETEDPhase 1/2815 miles

Radiation Therapy Using Holmium Ho 166 DOTMP Plus Melphalan and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma

NCT00004158

RATIONALE: Radiation therapy using holmium Ho 166 DOTMP may damage cancer cells. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy or radiation therapy used to kill cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of radiation therapy using holmium Ho 166 DOTMP plus melphalan and peripheral stem cell transplantation in treating patients who have multiple myeloma.

Multiple Myeloma and Plasma Cell Neoplasm

Fred Hutchinson Cancer CenterStarted Jun 1999

Miami, Florida, United States • Houston, Texas, United States • Seattle, Washington, United States +1 more locations

PreviousPage 943 of 985Next

in Illinois

Heart Diseasein Illinois